Managing immunosuppressive therapy in potentially cured post‐kidney transplant cancer (excluding non‐melanoma skin cancer): an overview of the available evidence and guidance for shared decision‐making - Hellemans - 2021 - Transplant International -
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets | Journal of Hematology & Oncology | Full Text
Frontiers | Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
Cancers | Free Full-Text | Mechanisms of Immunosuppression in Colorectal Cancer | HTML
Frontiers | Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
Frontiers | COVID-19 in Immunosuppressed Children
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets | Journal of Hematology & Oncology | Full Text
Tumor mutational burden and immunotherapy in gliomas: Trends in Cancer
Evaluation of Changes Over Time in the Drug Burden and Medication Regimen Complexity in ESRD Patients Before and After Renal Transplantation - ScienceDirect
Mutational burden, MHC-I expression and immune infiltration as limiting factors for in situ vaccination by TNFα and IL-12 gene electrotransfer - ScienceDirect
Immunosuppression following heart transplantation: prospects and challenges | Immunotherapy
IKKα-deficient lung adenocarcinomas generate an immunosuppressive microenvironment by overproducing Treg-inducing cytokines | PNAS
PDF) High immunosuppressive burden in advanced hepatocellular carcinoma patients: Can effector functions be restored?
Steering Transplant Immunosuppression by Measuring Virus-Specific T Cell Levels: The Randomized, Controlled IVIST Trial | American Society of Nephrology
Severe and multifaceted systemic immunosuppression caused by experimental cancers of the central nervous system requires release of non-steroid soluble mediators | bioRxiv
Immunosuppression - an overview | ScienceDirect Topics
Frontiers | Advances in Immune Monitoring Approaches for Sepsis-Induced Immunosuppression
Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States | American Society of Nephrology
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative - The Lancet Rheumatology
Frontiers | Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative - The Lancet Rheumatology
JCM | Free Full-Text | Post-Transplant Cyclophosphamide and Tacrolimus—Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA ...
The need for minimization strategies: current problems of immunosuppression - Bamoulid - 2015 - Transplant International - Wiley Online Library
Systemic immunity in cancer | Nature Reviews Cancer
Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer | Journal for ImmunoTherapy of Cancer
